This session will highlight how funding for HIV/AIDS has (and has not) strengthened health systems overall. Each panelist will address the question: Based on evidence collected so far, what conditions need to be present for HIV funding to strengthen health systems?
Global Health PolicySee more about Global Health Policy
- view as grid
- view as list
HIV epidemics among Men who have Sex with Men (MSM) are unfolding across Africa.
The Global Fund to fight AIDS, TB and Malaria was created in 2002 when the world realized it was failing to respond adequately to the AIDS epidemic, TB and malaria.
For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance.
Recent guidelines are all recommending that HIV treatment be started at a higher CD4 count because of issues such as the ongoing damage caused by HIV itself, and prevention of transmission. Issues in long-term treatment, such as potential side effects, the development of resistance, the cost and sustainability of programmes in resource-poor settings, are some of the potential problems for such a strategy.
HIV programs represent the first successful large-scale chronic disease program in resource-limited settings in history.
Human resources have challenged efforts to scale-up HIV prevention, care and treatment programs in low- and middle-income countries.
Following on the heels of The Lancet themed issue on HIV prevention launched at AIDS 2008, The Lancet has commissioned a series on the global HIV epidemic among people who use drugs.
AIDS 2010: Integrating Sexual and Reproductive Health and Rights (SRHR) and HIV: Lessons from the Field
At the International Conference on Population and Development in Cairo in 1994, governments worldwide agreed that sexual and reproductive health and rights include HIV services.
AIDS 2010: Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial
An update of current state of microbicide development will be provided. Speakers will provide a state of microbicide development update, safety and efficacy data from CAPRISA 004 and implications of the CAPRISA 004 trial results for the microbicide and PrEP field.